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Abstract 
Background and aims: Recently, the number of follicular helper T (Tfh) cells expressing interleukin (IL)-21 was found 
to increase in peripheral blood of human and murine models of autoimmune hepatitis (AIH). IL-21, the most recently 
discovered member of the type-I cytokine family, exerts various effects on the immune system, including B cell activa-
tion, plasma cell differentiation, and immunoglobulin production. We aimed to assess the relationship of serum IL-21 
levels in patients with type I AIH with clinical and laboratory parameters and histology.
Methods: Ninety-two Japanese patients with liver disease (22 AIH, 20 primary biliary cholangitis, 19 drug-induced 
liver injury, 8 acute hepatitis B, 8 chronic hepatitis C, 10 non-alcoholic steatohepatitis, 5 viral hepatitis) and 10 healthy 
volunteers were recruited. Serum IL-21 levels were detected by enzyme-linked immunosorbent assay. Real-time poly-
merase chain reaction measured mRNA levels of Bcl-6, IL-21, and CXCR5 (Tfh-related factors) in peripheral mononu-
clear cells.
Results: Mean age at diagnosis of AIH was 58.6 years, male-to-female ratio was 4:18, 18.2 % of participants had 
cirrhosis, and 22.7 % had severe disease. IL-21 levels were significantly increased in the serum of patients with AIH 
compared to those with other liver diseases and controls (p < 0.0001). Particularly, serum IL-21 levels were significantly 
increased in severe AIH cases compared to non-severe cases (p < 0.05). Serum IL-21 levels correlated positively with 
total serum bilirubin levels (r = 0.46, p < 0.05), grading of necroinflammatory activity (r = 0.68, p < 0.005) and nega-
tively with serum albumin levels in patients with AIH (r = −0.49, p < 0.05). In patients with biochemical remission of 
AIH, serum IL-21 levels remained elevated and correlated positively with serum IgG levels (r = 0.84, p < 0.01). Expres-
sion of Tfh-related factors, such as Bcl-6 and IL-21, in peripheral blood mononuclear cells of patients with AIH was 
significantly higher than that in healthy volunteers.
Conclusions: IL-21 may play an important role in the pathogenesis and severity of AIH, and may present a promising 
target for AIH therapy.
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Background
Autoimmune hepatitis (AIH) manifests as chronic liver 
inflammation of an unknown cause. It generally affects 
young to middle-aged women, and is associated with the 
presence of autoantibodies and hypergammaglobuline-
mia (Krawitt 1996). The histological features of interface 
hepatitis, i.e., the infiltration of lymphocytes, plasma 
cells, and macrophages, suggest the involvement of an 
aggressive cellular immune response in the pathogen-
esis of AIH (Vergani and Mieli-Vergani 2007). Human 
leukocyte antigen DR status affects the clinical fea-
tures of patients with type 1 AIH. In Japanese patients, 
DR4 is dominantly associated with the disease. AIH is 
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also associated with predominating Th1 responses and 
decreased function and number of regulatory T cells 
(Tregs) (Longhi et al. 2004, 2006).
Interleukin (IL)-21 is a member of the type I cyto-kine 
family (Zeng et  al. 2007). The mature form of human 
IL-21 consists of 131 amino acids. The cytokine is pro-
duced by activated natural killer (NK) T cells and multi-
ple CD4+ T cell subsets, including effector memory and 
central memory CD4+ T cells and differentiated T helper 
cell subsets polarized towards Th17 and T follicular 
helper (Tfh) phenotypes (Liu et  al. 2009; Parrish-Novak 
et  al. 2002; Wang et  al. 2011). IL-21 alone is capable of 
directly inducing both B lymphocyte induced maturation 
protein-1 (Blimp-1), which is required for plasma cell 
differentiation, and the transcription factor B cell lym-
phoma 6 (Bcl-6), which is required for germinal center 
reactions (Ettinger et al. 2008). Overexpression of IL-21 
in mice results in hypergammaglobulinemia and autoan-
tibody production (Ozaki et al. 2004).
Differentiated Tfh cells express IL-21, IL-21 recep-
tor (R), inducible costimulator (ICOS), CXC chemokine 
receptor (CXCR) 5, and programmed cell death protein-1 
(PD-1). IL-21 and ICOS are indispensable for Tfh cell 
generation and the helper function of B cells. Moreover, 
IL-21 can modulate the activity of CD8+ T cells and other 
immune and non-immune cells in  vivo. Since previous 
observations suggest that IL-21 and IL-21R may be asso-
ciated with immunoglobulin production, autoantibody 
production, and B lymphocyte hyperactivity (Ozaki et al. 
2002; Young et  al. 2007), IL-21 may be involved in the 
pathogenesis of autoimmune diseases. Elevated amounts 
of IL-21 have subsequently been reported in many auto-
immune diseases, including type 1 diabetes (King et  al. 
2004; McGuire et  al. 2009), rheumatoid arthritis (Young 
et  al. 2007; Sglunda et  al. 2014), systemic lupus erythe-
matosus (Ozaki et al. 2004; Bubier et al. 2009), Sjogren’s 
syndrome (Kang et al. 2011), inflammatory bowel diseases 
(Monteleone et al. 2005; Fina et al. 2008), and primary bil-
iary cholangitis (PBC) (Wang et al. 2015).
In a mouse model of spontaneous fatal AIH, splenic 
CD4+ T cells were localized in B cell follicles with huge 
germinal centers, expressed Bcl-6 inducible ICOS, IL-21, 
and IL-21R, and were of the Tfh cell phenotype. Blocking 
antibodies to ICOS or IL-21 suppressed Tfh cell genera-
tion and the induction of AIH in this model. In addition, 
IL-21 produced by Tfh cells drove CD8+ T cell activation. 
Splenic Tfh cells and CD8+ T cells were found to express 
C–C chemokine receptor 6 (CCR6), and C–C chemokine 
ligand 20 (CCL20) was elevated in the liver. Finally, 
administration of an anti-CCL20 antibody suppressed 
the migration of these T cells to the liver and induction 
of AIH (Aoki et al. 2011). In another study using the same 
mouse model, IL-18 and the CXCR3/CXC chemokine 
ligand 9 (CXCL9) axis were demonstrated to be critical 
for T cell differentiation and migration (Ikeda et al. 2014).
A few studies have linked serum IL-21 levels to clini-
cal outcomes in patients with AIH. For example, Ma 
et al. reported that the concentrations of serum IL-21 in 
patients with new onset AIH were correlated positively 
with serum immunoglobulin G (IgG), IgA, and IgM (Ma 
et  al. 2014). However, the roles of IL-21 in AIH remain 
poorly understood. This study aimed to assess the role 
of serum IL-21 in the pathogenesis and severity of type I 
AIH in Japanese patients.
Methods
Patients
Subjects were 22 patients with AIH, 20 with PBC, 19 with 
drug-induced liver injury (DILI), 8 with acute hepatitis B, 
8 with chronic hepatitis C (CHC), 10 with non-alcoholic 
steatohepatitis (NASH), and 5 with viral hepatitis, who 
received a diagnosis at Fukushima Medical University 
Hospital between 1997 and 2014, and 10 healthy con-
trols. As healthy controls, normal serum was taken from 
staff members of our department. The diagnosis of AIH 
was based on the revised and simplified International 
Autoimmune Hepatitis Group (IAIHG) scoring sys-
tem (Johnson and McFarlane 1993; Alvarez et  al. 1999; 
Hennes et al. 2008). Patients with other causes of chronic 
liver disease, particularly alcohol abuse, chronic hepatitis 
B, or CHC, were excluded from the AIH group. Patients 
were diagnosed as having PBC features if they met at 
least two of the following three criteria: (1) chronic ele-
vation of cholestatic liver enzymes alkaline phosphatase 
(ALP) and gamma-glutamyltranspeptidase (GTP) for at 
least 6 months; (2) presence of serum anti-mitochondrial 
antibody (AMA), detected by either indirect immuno-
fluorescence or ELISA using commercially available kits; 
and (3) typical histological findings from biopsied liver 
specimens (Lindor et al. 2009). The diagnosis of DILI was 
made by hepatologists at our hospital with due considera-
tion of alternative causes and reactions to drugs. In addi-
tion, confirmation of a NASH diagnosis was made by liver 
biopsy in the absence of other liver diseases. Viral hepati-
tis included that resulting from infection with 3 Epstein–
Barr viruses, 1 cytomegalovirus, and 1 hepatitis A virus.
Assessed data that were extracted retrospectively from 
patients’ medical charts included patient background (age, 
sex, onset type of disease, IAIHG score), clinical param-
eters at presentation [AST, ALT, ALP, TB, Alb, PLT, pro-
thrombin time (PT), IgG, antinuclear antibodies (ANA)] 
and at remission (ALT, ALP, TB, IgG), presence of relapse, 
cirrhosis, severity of disease, and therapeutic methods. 
Acute AIH was defined by the presence of acute onset of 
symptoms (e.g., jaundice and/or fatigue and/or anorexia) 
in conjunction with bilirubin >5 mg/dl and/or serum ALT 
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levels higher than tenfold the upper normal limit. Relapse 
of AIH was defined as an increase in serum transaminases 
to greater than twice the upper normal limit (ALT levels 
>90 U/l). Maintenance of serum transaminase levels of 
less than twice the upper limit of normal during follow-
up constituted a sustained remission. Liver cirrhosis was 
comprehensively diagnosed by liver biopsy findings and/or 
clinical parameters (including a PLT count of 10 × 104/μl 
or less and hyaluronic acid levels of 130 ng/ml or higher), 
presence of complications, and imaging findings (image 
pattern in abdominal ultrasound and CT findings). Disease 
severity was assessed with the diagnosis and treatment 
guide for AIH in Japan (Onji et al. 2014). Severe cases were 
defined as those that fulfilled at least one of the following: 
(1) clinical signs: (a) hepatic encephalopathy, (b) reduction 
or disappearance of hepatic dullness, (2) clinical labora-
tory tests: (a) AST/ALT > 200 U/l, (b) bilirubin > 5 mg/dl, 
(c) PT < 60 %, and (3) imaging tests: (a) hepatic atrophy, 
(b) heterogenous liver parenchyma pattern. Eight (36  %) 
of 22 patients with AIH who had achieved biochemical 
remission (defined as normal serum ALT and IgG levels) 
were assessed after 60.2 months (range 16–167) of treat-
ment. Serum cytokine and chemokine levels (IL-21, IL-18, 
CCL20, CCR6, CXCL9, CXCR3) were detected by using 
serum samples. The expression levels of Bcl-6, IL-21, and 
CXCR5 were measured by using mRNA in peripheral 
blood mononuclear cells (PBMCs). These samples were 
obtained at the time of diagnosis or remission and stored 
unthawed in several tubes at −20 °C until testing.
Ethics statement
This study was approved for the use of an opt-out con-
sent by the ethics committee of Fukushima Medical Uni-
versity School of Medicine. A website with additional 
information and including an opt-out consent was set 
up for the study. All patients agreed to serum testing and 
written informed consent was obtained. Retrospective 
testing of 92 blood samples from patients and volunteers 
was performed as part of the approved protocol and data 
were analyzed anonymously according to the institu-
tional and national ethics rules.
Enzyme‑linked immunosorbent assays (ELISA)
ELISA kits were used to determine the levels of serum 
IL-21 (Creative Diagnostics, NY, USA), IL-18 (MBL, 
Nagoya, Japan), CCL20, CXCL9 (R&D, Minneapolis, 
USA), CCR6 (CUSABIO, Hubei, China), and CXCR3 
(Cloud-clone, Houston, TX, USA), according to the man-
ufacturer’s instructions.
Quantitative RT‑PCR
Peripheral blood was drawn from patients with AIH 
and volunteers into a tube containing EDTA-2Na and 
centrifuged to separate PBMCs. RNA was reverse tran-
scribed to single stranded cDNA using the Random 
Primer, dNTP Mixture (Takara Shuzo Co., Ltd., Shiga, 
Japan) and RNasin® Ribonuclease Inhibitor (Promega, 
Madison, WI, USA), according to the manufacturer’s pro-
tocol. cDNA was used for quantitative analysis by PCR. 
Quantitative real time PCR (qPCR) was performed with a 
LightCycler 2.0 System (Roche Applied Science, Germany) 
using LightCycler DNA Master SYBR Green I (Roche 
Applied Science). PCR mixtures contained 0.5  μM sense 
and antisense primers. Samples were denatured at 95  °C 
for 10 min, followed by 45 cycles of annealing and exten-
sion at 95 °C for 15 s, 60 °C for 5 s, and 72 °C for 10 s. Melt-
ing curves were obtained at the end of amplification by 
cooling the samples to 65 °C for 15 s, followed by further 
cooling to 40 °C for 30 s. Data were analyzed by the stand-
ard curve method for relative quantification using Light-












AIH patients underwent liver biopsy with ultrasound 
guidance. Three patients were excluded from pathologi-
cal analysis: one because of ascites, and the other because 
of cirrhosis. Thus, 19 patients were included for further 
assessment. The liver sections stained by hematoxylin 
and eosin. Slides were coded and read by two pathologists 
who were unaware of the patient’s identity and history. 
Histological evaluation was performed according to the 
classification of Scheuer (1991) and Desmet et al. (1994). 
Grading of necroinflammatory activity (G) and staging of 
fibrosis (S) ranged from G 0–4 and S 0–4, respectively.
Statistical analyses
Results are expressed as mean  ±  SD. Differences were 
compared using the Mann–Whitney U-test and Wil-
coxon matched-pairs signed-rank test. Correlations 
between variables were assessed using Spearman’s rank 
correlation coefficient. To find the optimal cut-off level 
of TB, IL-21 and CCL20 that would distinguish between 
severe and non-severe necroinflammatory activity, 
receiver operating characteristic (ROC) curves were 
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used. Cut-off levels for parameters were set as the points 
closest to 100  % sensitivity and specificity. Multivariate 
logistic regression analysis was performed for univariate 
or multivariate analysis on factors related to the grad-
ing of necroinflammatory activity. All statistical analy-
ses were performed using Prism 6.0 software (GraphPad 
Software, Inc) and Excel Statistics (2011, Esumi, Co. Ltd., 
Tokyo, Japan). p < 0.05 was considered significant.
Results
Patients
Table 1 shows the characteristics of patients with AIH. In 
patients with AIH, male to female ratio was 4:18, mean 
age at diagnosis was 58.6 years. Acute and chronic AIH 
accounted for 50.0  % of patients each. Revised IAIHG 
scores averaged 15.1 points before treatment, and sim-
plified IAIHG scores averaged 6.2 points. Laboratory 
data at diagnosis were as follows: total bilirubin (TB), 
7.3 ±  9.7 mg/dl; ALT, 537.8 ±  732.1 U/l; alkaline phos-
phatase (ALP), 440.8  ±  240.6 U/l; Alb, 3.3  ±  0.7  g/dl; 
and PT, 72.9  ±  22.9  %. Serum IgG at onset was 
2604.1 ±  1021.7  mg/dl. The median titer of antinuclear 
antibodies (ANA) was 1:160. Five patients (22.7  %) had 
severe disease. The grading of necroinflammatory activity 
was G0 (0/19, 0 %), G1 (2/19, 10.5 %), G2 (9/19, 47.4 %), 
G3 (7/19, 36.8 %), G4 (1/19, 5.3 %). The staging of fibro-
sis was F0 (2/19, 10.5  %), F1 (4/19, 21.1  %), F2 (5/19, 
26.3 %), F3 (6/19, 31.6 %), F4 (2/19, 10.5 %). With respect 
to therapy, most patients (72.7 %) were treated with pred-
nisolone (PSL) alone; three (13.6  %) were treated with 
ursodeoxycholic acid (UDCA) alone, and three (13.6 %) 
were treated with azathioprine (AZA) in combination 
with PSL. When clinical parameters at remission were 
compared with those at onset, ALT (13.3  ±  6.9 U/l), 
ALP (239.8 ±  81.6 U/l), TB (0.9 ±  0.4  mg/dl), and IgG 
(1236.5 ± 249.6 mg/dl) were significantly lower and were 
within the normal range. Characteristics of patients with 
other liver diseases are summarized in Additional file 1: 
Table 1. 
Patients with AIH have higher serum IL‑21 levels 
than those with other liver diseases and healthy controls
The mean titer of IL-21 by ELISA in serum samples 
from patients with AIH (294.3  pg/ml) was significantly 
higher than in those with DILI (72.8 pg/ml, p < 0.0001), 
PBC (74.1 pg/ml, p < 0.0001), acute hepatitis B (52.6 pg/
ml, p  <  0.0001), CHC (60.8  pg/ml, p  <  0.0001), NASH 
(37.9 pg/ml, p < 0.0001), and viral hepatitis (78.6 pg/ml, 
p < 0.0001), and in sera from healthy volunteers (46.9 pg/
ml, p < 0.0001) (Fig. 1).
Table 1 Characteristics of patients with autoimmune hep-
atitis
AIH autoimmune hepatitis, AST aspartate aminotransferase (normal: 13–33 
U/l), ALT alanine aminotransferase (normal: 6–27 U/l), ALP alkaline phosphatase 
(normal: 115–359 U/l), IgG immunoglobulin G (normal: 870–1700 mg/dl), 
ANA antinuclear antibody (normal: 0–39×), UDCA ursodeoxycholic acid, PSL 
prednisolone, AZA azathioprine
Age (year) 58.6 ± 11.7
Gender (male/female) 4/18
Onset type (acute/chronic) 11/11
AIH score (revised) 15.1 ± 4.0
AIH score (simplified) 6.2 ± 1.3
AST (U/l) 613.4 ± 831.1
ALT (U/l) onset/remission 537.8 ± 732.1/13.3 ± 6.9
ALP (U/l) onset/remission 440.8 ± 240.6/239.8 ± 81.6
Alb (g/dl) 3.3 ± 0.7
TB (mg/dl) onset/remission 7.3 ± 9.7/0.9 ± 0.4
PT (%) 72.9 ± 22.9
PLT (×104/μl) 15.0 ± 5.1
IgG (mg/dl) onset/remission 2604.1 ± 1021.7/1236.5 ± 249.6
ANA (median) 160
Relapse n (%) 7 (31.8)
Grading of necroinflammatory activity 
0/1/2/3/4 (n)
0/2/9/7/1
Staging of fibrosis 0/1/2/3/4 (n) 2/4/5/6/2
UDCA monotherapy n (%) 3 (13.6)
PSL monotherapy n (%) 16 (72.7)











































Fig. 1 Patients with AIH have higher serum IL-21 levels than those 
with other liver diseases and healthy controls. p values were calcu-
lated with the Mann–Whitney test (*p < 0.0001)
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Expression of Tfh‑related factors in peripheral blood 
mononuclear cells of patients with AIH
As shown in Fig. 2, there were significant differences in 
the mRNA expression of follicular helper T (Tfh)-related 
factors in PBMCs between healthy controls and patients 
with AIH. Expression of Tfh-related factors, such as Bcl-
6, IL-21, and CXCR5, in patients with AIH was signifi-
cantly higher compared to that in healthy controls.
Comparison between patients with severe and non‑severe 
AIH at presentation
As shown in Table  2, patients with AIH were also 
assessed by severity of disease. When patient background 
and clinical parameters at diagnosis were compared 
between patients with severe and non-severe (mild and 
moderate) AIH, Alb (2.7 vs. 3.5  g/dl, p  <  0.05) and PT 
(46.4 vs. 81.3 %, p < 0.005) were significantly lower in the 
severe AIH group, and serum IL-21 (396.7 vs. 264.7 pg/
ml, p < 0.05) and IL-18 (1776.6 vs. 808.6 pg/dl, p < 0.05) 
were significantly higher in the severe AIH group.
Relationship between serum IL‑21 and clinical 
presentation
Serum IL-21 levels were significantly and positively cor-
related with TB, CCL20, CXCL9, and CXCR3 levels, and 
negatively correlated with Alb levels (Table 3).
Relationship between serum IL‑21 and histology
Spearman’s rank coefficient analysis showed in Fig.  3. 
Although serum IL-21 levels did not correlate with 
staging of fibrosis (r =  0.45, p =  0.056), they were sig-
nificantly positively correlated with grading of necro-
inflammatory activity (r  =  0.68, p  <  0.005). As shown 






















Fig. 2 Expression of Tfh-related factors in peripheral blood mononuclear cells of patients with AIH. p values were calculated with the Mann–Whit-
ney test
Table 2 Comparison of clinical and laboratory parameters between severe and non-severe autoimmune hepatitis
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, IgG immunoglobulin G, IL-21 interleukin 21, IL-18 interleukin 18, CCL20 C–C 
chemokine ligand 20, CCR6 C–C chemokine receptor 6, CXCL9 CXC chemokine ligand 9, CXCR3 CXC chemokine receptor 3
p values were calculated with the Mann–Whitney U test (*statistically significant)
Non‑severe (n = 17)
Mild (n = 4) Moderate (n = 13) Severe (n = 5) p
ALT (U/l) 96 ± 66 599 ± 858 729 ± 590 0.2488
Alb (g/dl) 4.0 ± 0.2 3.4 ± 0.6 2.7 ± 0.8 <0.05*
TB (mg/dl) 0.9 ± 0.3 7.5 ± 10.7 12.0 ± 8.9 0.1138
PT (%) 95.5 ± 2.8 77.9 ± 19.4 46.4 ± 12.2 <0.005*
PLT (×104/μl) 20.9 ± 5.4 14.6 ± 4.4 11.5 ± 2.9 0.1117
IgG (mg/dl) 2834 ± 725 2415 ± 1112 2910 ± 1042 0.4455
IL-21 (pg/ml) 244.5 ± 146.6 270.3 ± 173.4 396.7 ± 99.9 <0.05*
IL-18 (pg/ml) 366.2 ± 213.2 944.8 ± 846.9 1776.6 ± 891.2 <0.05*
CCL20 (pg/ml) 58.4 ± 45.9 215.3 ± 316.9 255.2 ± 247.7 0.2488
CCR6 (pg/ml) 26.2 ± 9.2 147.8 ± 133.7 163.9 ± 71.2 0.1196
CXCL9 (pg/ml) 1206.7 ± 1370.2 1419.9 ± 1004.9 1953.5 ± 903.1 0.2488
CXCR3 (ng/ml) 43.7 ± 61.0 54.4 ± 34.7 86.8 ± 47.5 0.1012
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progression of necroinflammatory activity. When clini-
cal and laboratory parameters at diagnosis were com-
pared between severe necroinflammatory activity (G 
3–4) and non-severe (G 0–2) in liver histology, TB (3.2 
vs. 11.0  mg/dl, p  <  0.05), IL-21 (211.7 vs. 414.9  pg/ml, 
p  <  0.01) and CCL20 (55.4 vs. 329.3  pg/ml, p  <  0.01) 
were significantly higher in the severe group. The results 
of multivariate logistic regression analysis using the 3 
factors, significantly associated with severe necroin-
flammatory activity, were shown in Table 5. To find the 
optimal cut-off level of TB, IL-21 and CCL20 that would 
distinguish between severe and non-severe necroin-
flammatory activity, ROC curves were used. It was set 
at more than 5.2  mg/dl in TB (p  <  0.05) at more than 
296  pg/ml in serum IL-21 (p  <  0.01) and at more than 
71  pg/ml in serum CCL20 (p  <  0.01). With the signifi-
cant factors extracted by univariate analysis, multivariate 
analysis was performed, and IL-21 of more than 296 pg/
ml was independent factors.  
Relationship between serum IL‑21 and IgG levels at onset 
and remission in patients with AIH
The relationship between serum IL-21 and IgG levels in 
patients with AIH is shown in Fig.  4. Serum IL-21 lev-
els were significantly higher in patients with acute AIH 
compared to those with chronic AIH (p < 0.05). Although 
serum IL-21 levels did not significantly correlate with 
serum IgG levels in patients with acute AIH, they were 
significantly and positively correlated with serum IgG 
levels in those with chronic AIH. Surprisingly, serum 
IL-21 levels did not significantly differ in patients with 
AIH at onset and remission. Serum IL-21 levels were sig-
nificantly and positively correlated with serum IgG levels 
in patients with AIH at remission (p < 0.005).
Discussion
The main finding of this study was that serum IL-21 lev-
els were significantly increased in the serum of patients 
with AIH compared to those with other liver diseases and 
controls. In particular, serum IL-21 levels were signifi-
cantly increased in patients with severe AIH compared to 
Table 3 Relationship between serum IL-21 levels and clini-
cal presentation in patients with autoimmune hepatitis
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline 
phosphatase, IgG immunoglobulin G, ANA antinuclear antibody, IL-18 
interleukin-18, CCL20 C–C chemokine ligand 20, CCR6 C–C chemokine receptor 
6, CXCL9 CXC chemokine ligand 9, CXCR3 CXC chemokine receptor 3
p values were calculated with the Spearman rank correlation test (*statistically 
significant)
Variable r p
AST (U/l) 0.2716 0.2215
ALT (U/l) 0.2433 0.2753
ALP (U/l) 0.2366 0.2890
Alb (g/dl) −0.4951 <0.05*
TB (mg/dl) 0.4641 <0.05*
PT (%) −0.3587 0.1103
PLT (×104/μl) −0.2981 0.1778
IgG (mg/dl) 0.2928 0.1860
ANA (median) 0.0335 0.8853
IL-18 (pg/ml) 0.1158 0.6079
CCL20 (pg/ml) 0.5987 <0.005*
CCR6 (pg/ml) 0.4151 0.0547
CXCL9 (pg/ml) 0.4999 <0.05*
CXCR3 (ng/ml) 0.5016 <0.05*





Staging of fibrosisGrading of necroinflammatory
activity
ba
Fig. 3 Relationship between serum IL-21 and histology. Serum IL-21 levels according to the degree of necroinflammatory activity and liver fibrosis. 
a Grading of necroinflammatory activity, b staging of fibrosis. Although serum IL-21 levels did not correlate with staging of fibrosis (r = 0.45,  
p = 0.056), they were significantly positively correlated with grading of necroinflammatory activity (r = 0.68, p < 0.005). p values were calculated 
with Spearman rank correlation test
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those with non-severe AIH. Moreover, serum IL-21 lev-
els were significantly positively correlated with grading of 
necroinflammatory activity in liver histology.
In a previous study, serum IL-21 levels in patients with 
chronic hepatitis B (CHB) and hepatitis B-related acute-
on-chronic liver failure were significantly increased com-
pared to levels in healthy controls (Hu et  al. 2011). In 
another study, serum IL-21 levels at treatment week 12 
were significantly higher in CHB patients who achieved a 
complete response, compared to those who did not (Ma 
et al. 2012). In the present study, serum IL-21 levels were 
not increased in patients with acute hepatitis B.
In a recent report, patients with PBC were found not 
only to have increased Tfh cells, but also increased IL-21 
levels and B cell activation, disease severity, and respon-
siveness to UDCA therapy (Wang et al. 2015). Our results 
showed that serum IL-21 levels in some patients with 
PBC were increased, and that the levels in patients with 
AIH were significantly higher than in those with DILI. 
DILI with features of autoimmunity represents an impor-
tant category of hepatotoxicity due to medication expo-
sure. In daily clinical practice, distinguishing DILI from 
acute AIH is often difficult (Suzuki et al. 2011; Fujiwara 
and Yokosuka 2012), and in this context, serum IL-21 
could potentially be useful for differential diagnosis.
Several studies have demonstrated a correlation 
between the severity of autoimmune diseases and IL-21 
levels (Choi et al. 2015; Szabo et al. 2013; He et al. 2012; 
Table 4 Comparison of  clinical and  laboratory parameters between  severe and  non-severe grading of  necroinflamma-
tory activity in liver histology
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, IgG immunoglobulin G, IL-21 interleukin 21, IL-18 interleukin 18, CCL20 C–C 
chemokine ligand 20, CCR6 C–C chemokine receptor 6, CXCL9 CXC chemokine ligand 9, CXCR3 CXC chemokine receptor 3
p values were calculated with the Mann–Whitney U test (*statistically significant)
Grading of necroinflammatory  
activity: G0–2 (n = 11)
Grading of necroinflammatory  
activity: G3–4 (n = 8)
p
ALT (U/l) 420 ± 426 818 ± 1088 0.3484
Alb (g/dl) 3.5 ± 0.8 3.0 ± 0.8 0.0860
TB (mg/dl) 3.2 ± 6.4 11.0 ± 9.6 <0.05*
PT (%) 68.7 ± 28.4 74.1 ± 18.6 0.9150
PLT (×104/μl) 16.5 ± 6.2 13.1 ± 4.2 0.2014
IgG (mg/dl) 2307 ± 1131 2836 ± 548 0.1767
IL-21 (pg/ml) 211.7 ± 135.3 414.9 ± 142.7 <0.01*
IL-18 (pg/ml) 903.8 ± 667.4 1069.2 ± 891.9 0.8910
CCL20 (pg/ml) 55.4 ± 62.5 329.3 ± 302.8 <0.01*
CCR6 (pg/ml) 113.3 ± 112.6 142.5 ± 99.1 0.4381
CXCL9 (pg/ml) 1356.8 ± 1036.9 2020.8 ± 963.6 0.1084
CXCR3 (ng/ml) 51.7 ± 43.6 82.9 ± 41.6 0.1084
Table 5 Factors related to grading of necroinflammatory activity (G3–G4 vs. G0–G2): univariate analysis and multivariate 
analysis
Ref reference group, IL-21 interleukin 21, CCL20 C–C chemokine ligand 20
p values were calculated with multiple logistic regression analysis (*statistically significant)
Factors Univariate analysis Multivariate analysis
OR 95 % CI p OR 95 % CI p
TB (mg/dl)
 5.2> 1 (Ref ) 1 (Ref )
 5.2< 7.50 0.91–61.93 0.061 4.73 0.12–178.76 0.402
IL-21 (pg/ml)
 296> 1 (Ref ) 1 (Ref )
 296< 31.50 2.53–392.92 <0.01* 23.94 1.15–499.49 <0.05*
CCL20 (pg/ml)
 71> 1 (Ref ) 1 (Ref )
 71< 12.25 1.35–111.01 <0.05* 1.23 0.03–43.26 0.910
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Rasmussen et al. 2010). In the present study, serum IL-21 
levels were significantly higher in the severe AIH group 
and positively correlated with serum TB, CCL20, CXCL9 
and CXCR3 levels. In a mouse model of AIH, blocking 
IL-21 suppressed Tfh cell generation and the induction of 
AIH, and IL-21 produced by Tfh cells was shown to drive 
CD8+ T-cell activation (Aoki et al. 2011). Hepatic mac-
rophages/Kupffer cells producing CXCL9 are critical for 
the migration of CXCR3-expressing T cells, and dendritic 
cell-derived IL-18 is important for the differentiation of 
Th1 cells and CD8+ effector T cells (Ikeda et  al. 2014). 
These systems may serve as targets for treating patients 
with severe AIH. As demonstrated in the present study, 
serum IL-21 levels, with a cut-off of 296 pg/ml, may pre-
dict the progression of necroinflammatory activity in 
liver histology.
A recent nationwide survey suggested that serum IgG 
levels at the onset of AIH decreased compared with those 
in a previous study (Abe et al. 2011). In addition, patients 
with acute AIH occasionally present with lower serum IgG 
levels and/or the absence or low titers of serum autoanti-
bodies (Onji 2011). In the present study, serum IL-21 levels 
were significantly higher in patients with acute AIH com-














































































Fig. 4 Relationship between serum IL-21 and IgG levels at onset and remission in patients with AIH. a Comparison between AIH patients at onset 
of acute (n = 11) or chronic (n = 11) presentation. b Relationship between serum IL-21 levels and serum IgG levels in patients with AIH at onset of 
acute AIH. c Relationship between serum IL-21 levels and serum IgG levels in patients with AIH at onset of chronic AIH. d Comparison between AIH 
patients at onset and remission (n = 8). e Relationship between serum IL-21 levels and serum IgG levels in patients with AIH at remission. p values 
were calculated with the Mann–Whitney test, Spearman rank correlation test, or Wilcoxon matched-pairs signed-rank test, ns not significant
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levels were not significantly correlated with serum IgG lev-
els in acute AIH, they were significantly and positively cor-
related with serum IgG levels in chronic AIH.
In patients with AIH in biochemical remission, serum 
IL-21 levels were still elevated, despite a reduction in 
serum IL-18, CCL20, CCR6, CXCL9, and CXCR3 lev-
els (Additional file  2: Figure  1), and significantly and 
positively correlated with serum IgG levels. Biochemi-
cal remission is typically defined as the normalization 
of serum transaminases and IgG. The Mayo Clinic trial 
showed that histological remission lagged behind bio-
chemical remission by several months and was achieved 
by only 60  % of patients after 2-year treatment with 
PSL ± AZA (Soloway et al. 1972). Another report showed 
that persistent histological activity, despite biochemical 
remission, is frequently observed in patients treated for 
AIH and is associated with lower rates of fibrosis regres-
sion and reduced long-term survival (Dhaliwal et  al. 
2015).
This study has several limitations. First, the expression 
of Tfh-related factors, such as Bcl-6, CXCR5 and IL-21, 
in peripheral blood mononuclear cells of patients with 
AIH was significantly increased compared to the expres-
sion in healthy volunteers. However, the expression of 
these factors in liver tissue was not investigated. Second, 
the sample population was relatively small. Finally, this 
study was retrospective in design, and thus our results 
will need to be confirmed in a prospective study.
Conclusions
Our findings suggest that IL-21 may play an important 
role in the pathogenesis and severity of AIH. Further 
research on the systemic and localized effects of IL-21 in 
AIH will provide a basis for targeted therapy that could 
benefit this patient population.
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